Drug Profile
Cannabinol ophthalmic - InMed Pharmaceuticals
Alternative Names: CTI-085; INM 085; INM-088Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Cannabis Technologies
- Developer InMed Pharmaceuticals; University of Debrecen
- Class Antiallergics; Antiglaucomas; Cannabinoids; Eye disorder therapies; Neuroprotectants; Phytotherapies; Skin disorder therapies
- Mechanism of Action Apoptosis inhibitors; Cannabinoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Glaucoma
- Discontinued Hypersensitivity